Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Biomarkers

GDF-15 and risk stratification in atrial fibrillation

Nature Reviews Cardiology volume 12, pages 8–9 (2015)Cite this article

Subjects

Biomarkers are needed to accurately represent or predict clinical outcomes for optimal management of patients with atrial fibrillation (AF) in clinical practice. Growth differentiation factor-15, a member of the transforming growth factor-β family, has an independent prognostic role for major bleeding and death in patients with AF receiving oral anticoagulation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857–867 (2007).

    Article  PubMed  Google Scholar 

  2. Camm, A. J. et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33, 2719–2747 (2012).

    PubMed  Google Scholar 

  3. Lip, G. Y. Stroke and bleeding risk assessment in atrial fibrillation: when, how and why? Eur. Heart J. 34, 1041–1049 (2013).

    Article  CAS  PubMed  Google Scholar 

  4. Walletin, L. et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from ARISTOTLE trial. Circulation http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011204.

  5. Watson, T., Shantsila, E. & Lip, G. Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 373, 155–166 (2009).

    Article  CAS  PubMed  Google Scholar 

  6. Hijazi, Z., Oldgren, J., Siegbahn, A., Granger, C. B. & Wallentin, L. Biomarkers in atrial fibrillation: a clinical review. Eur. Heart J. 34, 1475–1480 (2013).

    Article  CAS  PubMed  Google Scholar 

  7. Roldan, V. et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J. Thromb. Haemost. 10, 1500–1507 (2012).

    Article  CAS  PubMed  Google Scholar 

  8. Gallagher, A. M., Setakis, E., Plumb, J. M., Clemens, A. & van Staa, T. P. Risk of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb. Haemost. 106, 968–977 (2011).

    Article  CAS  PubMed  Google Scholar 

  9. Depta, J. P. & Bhatt, D. L. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb. Haemost. 104, 657–663 (2010).

    Article  CAS  PubMed  Google Scholar 

  10. Goto, S. et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am. Heart J. 156, 855–863. e2 (2008).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are supported by RD12/0042/0049 (RETICS) from ISCIII and PI13/00513/FEDER from ISCIII.

Author information

Authors and Affiliations

  1. Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, University of Murcia, Carretera Madrid-Cartagena s/n, El Palmar, 30120, Spain

    Francisco Marín

  2. Hematology and Medical Oncology Unit, Hospital Universitario Morales Meseguer, University of Murcia, Avda de los Vélez s/n, Murcia, 30008, Spain

    Vanessa Roldán

Authors
  1. Francisco Marín
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vanessa Roldán
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francisco Marín.

Ethics declarations

Competing interests

F.M. has received funding for research, consultancy, and lecturing from Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo. V.R. has received funding for consultancy and lecturing from Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marín, F., Roldán, V. GDF-15 and risk stratification in atrial fibrillation. Nat Rev Cardiol 12, 8–9 (2015). https://doi.org/10.1038/nrcardio.2014.190

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2014.190

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing